These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 39122631)

  • 1. Interferonopathies: From concept to clinical practice.
    Mendonça LO; Frémond ML
    Best Pract Res Clin Rheumatol; 2024 Sep; 38(3):101975. PubMed ID: 39122631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.
    Kim H; Sanchez GA; Goldbach-Mansky R
    J Mol Med (Berl); 2016 Oct; 94(10):1111-1127. PubMed ID: 27678529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.
    Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
    Ann Rheum Dis; 2022 May; 81(5):601-613. PubMed ID: 35086813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS.
    Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
    Arthritis Rheumatol; 2022 May; 74(5):735-751. PubMed ID: 35315249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic insights from genetic causes of autoinflammatory inflammasomopathies and interferonopathies.
    Lin B; Goldbach-Mansky R
    J Allergy Clin Immunol; 2022 Mar; 149(3):819-832. PubMed ID: 34893352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Expression of Interferon-Alpha Protein Provides Clues to Tissue Specificity Across Type I Interferonopathies.
    Lodi L; Melki I; Bondet V; Seabra L; Rice GI; Carter E; Lepelley A; Martin-Niclós MJ; Al Adba B; Bader-Meunier B; Barth M; Blauwblomme T; Bodemer C; Boespflug-Tanguy O; Dale RC; Desguerre I; Ducrocq C; Dulieu F; Dumaine C; Ellul P; Hadchouel A; Hentgen V; Hié M; Hully M; Jeziorski E; Lévy R; Mochel F; Orcesi S; Passemard S; Pouletty M; Quartier P; Renaldo F; Seidl R; Shetty J; Neven B; Blanche S; Duffy D; Crow YJ; Frémond ML
    J Clin Immunol; 2021 Apr; 41(3):603-609. PubMed ID: 33411153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Type I interferonopathies].
    Munoz J; Marque M; Dandurand M; Meunier L; Crow YJ; Bessis D
    Ann Dermatol Venereol; 2015 Nov; 142(11):653-63. PubMed ID: 26363997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.
    Li W; Wang W; Wang W; Zhong L; Gou L; Wang C; Ma J; Quan M; Jian S; Tang X; Zhang Y; Wang L; Ma M; Song H
    Front Immunol; 2022; 13():825367. PubMed ID: 35418997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review.
    Gómez-Arias PJ; Gómez-García F; Hernández-Parada J; Montilla-López AM; Ruano J; Parra-Peralbo E
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):733-750. PubMed ID: 33856640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung Inflammation in STING-Associated Vasculopathy with Onset in Infancy (SAVI).
    David C; Frémond ML
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.
    Yu ZX; Song HM
    World J Pediatr; 2020 Feb; 16(1):44-51. PubMed ID: 31377974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
    Kanazawa N; Ishii T; Takita Y; Nishikawa A; Nishikomori R
    Pediatr Rheumatol Online J; 2023 Apr; 21(1):38. PubMed ID: 37087470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STING palmitoylation as a therapeutic target.
    Hansen AL; Mukai K; Schopfer FJ; Taguchi T; Holm CK
    Cell Mol Immunol; 2019 Mar; 16(3):236-241. PubMed ID: 30796349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay of Cyclic GMP-AMP Synthase/Stimulator of IFN Genes and Toll-Like Receptor Nucleic Acid Sensing Pathways in Autoinflammation and Abnormal Bone Formation due to DNaseII-Deficiency.
    Marshak-Rothstein A; Manning CA; Baum R; Pawaria S; Gravallese EM
    Viral Immunol; 2020 Apr; 33(3):246-249. PubMed ID: 32286184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics.
    Melki I; Frémond ML
    Curr Rheumatol Rep; 2020 Jun; 22(7):32. PubMed ID: 32548765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling.
    Hansen AL; Buchan GJ; Rühl M; Mukai K; Salvatore SR; Ogawa E; Andersen SD; Iversen MB; Thielke AL; Gunderstofte C; Motwani M; Møller CT; Jakobsen AS; Fitzgerald KA; Roos J; Lin R; Maier TJ; Goldbach-Mansky R; Miner CA; Qian W; Miner JJ; Rigby RE; Rehwinkel J; Jakobsen MR; Arai H; Taguchi T; Schopfer FJ; Olagnier D; Holm CK
    Proc Natl Acad Sci U S A; 2018 Aug; 115(33):E7768-E7775. PubMed ID: 30061387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulation of the cGAS-STING Pathway in Monogenic Autoinflammation and Lupus.
    Wobma H; Shin DS; Chou J; Dedeoğlu F
    Front Immunol; 2022; 13():905109. PubMed ID: 35693769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic interferonopathies: An overview.
    Eleftheriou D; Brogan PA
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):441-459. PubMed ID: 29773266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I interferonopathies in pediatric rheumatology.
    Volpi S; Picco P; Caorsi R; Candotti F; Gattorno M
    Pediatr Rheumatol Online J; 2016 Jun; 14(1):35. PubMed ID: 27260006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease.
    Ahn J; Barber GN
    Curr Opin Immunol; 2014 Dec; 31():121-6. PubMed ID: 25459004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.